Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001714899-24-000056
Filing Date
2024-02-13
Accepted
2024-02-13 20:22:03
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3612
  Complete submission text file 0001714899-24-000056.txt   5044
Mailing Address 863 MITTEN ROAD, SUITE 102 BURLINGAME CA 94010
Business Address
Krognes Steve E. (Reporting) CIK: 0001666236 (see all company filings)

Type: 144

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-38311 | Film No.: 24631388
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)